- Home
- CEF vs ALKS Comparison
CEF vs ALKS Comparison
Compare CEF & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEF
- ALKS
- Stock Information
- Founded
- CEF N/A
- ALKS 1987
- Country
- CEF
- ALKS Ireland
- Employees
- CEF N/A
- ALKS N/A
- Industry
- CEF
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- CEF
- ALKS Health Care
- Exchange
- CEF NYSE
- ALKS Nasdaq
- Market Cap
- CEF 5.8B
- ALKS 5.1B
- IPO Year
- CEF N/A
- ALKS 1991
- Fundamental
- Price
- CEF $30.36
- ALKS $29.09
- Analyst Decision
- CEF
- ALKS Buy
- Analyst Count
- CEF 0
- ALKS 12
- Target Price
- CEF N/A
- ALKS $40.00
- AVG Volume (30 Days)
- CEF N/A
- ALKS 1.6M
- Earning Date
- CEF N/A
- ALKS 07-23-2025
- Dividend Yield
- CEF N/A
- ALKS N/A
- EPS Growth
- CEF N/A
- ALKS N/A
- EPS
- CEF N/A
- ALKS 2.09
- Revenue
- CEF N/A
- ALKS $1,513,770,000.00
- Revenue This Year
- CEF N/A
- ALKS N/A
- Revenue Next Year
- CEF N/A
- ALKS $4.25
- P/E Ratio
- CEF N/A
- ALKS $13.92
- Revenue Growth
- CEF N/A
- ALKS N/A
- 52 Week Low
- CEF N/A
- ALKS $22.90
- 52 Week High
- CEF N/A
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- CEF 56.20
- ALKS 38.82
- Support Level
- CEF $30.60
- ALKS $29.26
- Resistance Level
- CEF $30.93
- ALKS $30.52
- Average True Range (ATR)
- CEF 0.29
- ALKS 0.78
- MACD
- CEF 0.02
- ALKS -0.24
- Stochastic Oscillator
- CEF 52.14
- ALKS 4.96
About CEF SPROTT PHYSICAL GOLD AND SILVER TR
Sprott Physical Gold and Silver Trust is a closed end mutual fund trust. The trust invests and holds all of its assets in physical gold and silver bullion and seeks to provide a secure, convenient and exchange-traded investment alternative for investors interested in holding physical bullion without the inconvenience that is typical of direct investment.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.